1601 TRAPELO ROAD, WALTHAM, MA
Other Events
Announces Leadership Transition
Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Material disclosure
Stockholders Approve Amendment to 2013 Equity Incentive Plan
Annual Report to Security Holders
Appoints Dr. Inderjit Kaul to the Board of Directors
Minerva Neurosciences Secures $200M for Roluperidone Phase 3 Trial in Schizophrenia
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Correspondence
Submission Upload